-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

216 Phase I/II Study of the All-Oral Combination of Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax (SAVE) in R/R AML

Program: Oral and Poster Abstracts
Type: Oral
Session: 616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Menin Inhibitors in AML
Hematology Disease Topics & Pathways:
AML, Combination therapy, Research, Clinical trials, Acute Myeloid Malignancies, Drug development, Clinical Research, Diseases, Treatment Considerations, Myeloid Malignancies
Saturday, December 7, 2024: 3:15 PM

Ghayas C. Issa, MD1, Branko Cuglievan, MD2, Naval Daver, MD3, Courtney D. DiNardo, MD, MSc1, Aziz Farhat4*, Nicholas J. Short, MD1, David McCall, MD2, Allison Pike, RN1*, Sheila Tan, RN1*, Brianna Kammerer, BSN, MS, RN5*, Aimee Marshal1*, Musa Yilmaz, MD1*, Tapan M. Kadia, MD1, Naveen Pemmaraju, MD1, Maro Ohanian, DO1*, Hussein A. Abbas, MD, PhD1, Abhishek Maiti, MBBS6, Alexandre Bazinet, MD1*, Elias Jabbour, MD1, Koji Sasaki, MD1, Gautam Borthakur, MD7, Guillermo Montalban-Bravo, MD1, Nitin Jain, MD1, Yesid Alvarado Valero, MD1, Farhad Ravandi, MBBS8, Guillermo Garcia-Manero, MD1, Michael Andreeff, MD, PhD7 and Hagop M. Kantarjian, MD1

1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
2Division of Pediatrics, MD Anderson Cancer Center, Houston, TX
3MD Anderson Cancer Center, Houston, TX
4The University of Texas MD Anderson Cancer Center, Houston, TX
5Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX
6Department of Leukemia, The University of Texas Health Science Center At Houston, Houston, TX
7Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
8Department of Leukemia, University of Texas- MD Anderson Cancer Center, Houston, TX

Background: The menin inhibitor revumenib (previously SNDX-5613), is a potent, oral, selective inhibitor of the menin–KMT2A interaction which is a dependency in acute leukemia caused by either rearrangement of the KMT2A (KMT2Ar) or Nucleoporin 98 (NUP98r) genes, or mutation of the Nucleophosmin 1 gene (NPM1mt). KMT2Ar or NPM1mt leukemias are highly susceptible to induction of apoptosis through BCL2 inhibition, and dual Bcl-2 and menin inhibition led to synergistic activity in KMT2Ar or NPM1mt leukemia models (Carter BZ, Blood 2021; Fiskus W, BCJ 2022). Therefore, we designed a phase I/II, investigator-initiated trial of the all-oral combination of revumenib, venetoclax and the hypomethylating agent ASTX727 in children and adults with relapsed/refractory (R/R) acute myeloid leukemia (AML) (NCT05360160).

Methods: Patients (pts) with R/R AML or myeloid mixed-lineage acute leukemia (MPAL) aged 12 years and older were eligible. Dose escalation followed a 3+3 design. ASTX727 (decitabine/ cedazuridine) was administered at 35 mg/100 mg PO daily days 1-5, venetoclax at 400 mg (target dose) PO daily days 1-14, and revumenib 113 mg PO Q12h (dose level [DL] 0) or 163 mg PO Q12h (DL 1, used in phase II monotherapy), days 1-28 with either posaconazole or voriconazole (strong CYP3A4 inhibitors). Revumenib monotherapy following hematopoietic stem cell transplant (HSCT) was resumed for 1-year maintenance. An amendment to the protocol recommended holding revumenib after day 21 if cycle 1 day 14 bone marrow (BM) showed blasts <5%. Measurable residual disease (MRD) was assessed using multicolor flow cytometry (sensitivity 10-4).

Results: As of 7/22/2024, 26 pts were enrolled, 12 pts on the phase I (6 pts for each DL), and 14 pts on the phase II. The recommended phase 2 dose for revumenib in this combination was identified as 163 mg PO Q12h with strong CYP3A4 inhibitors. The median age was 35 years (range, 12-79 years), including 5 children (age <18 years). Eleven pts had KMT2Ar (42%), 10 had NPM1mt (38%), 5 had NUP98r (20%), and 4 (15%) had extramedullary disease (EMD). The median prior lines of therapy was 3 (range 1-5), 17 pts (65%) had prior venetoclax, 11 pts (42%) had prior HSCT, and 2 pts had prior menin inhibitor. The most common all-grade treatment-emergent adverse events (TEAEs) were QT prolongation (58%), AST/ALT elevation (54%), febrile neutropenia (46%), hyperphosphatemia (46%), nausea (42%). Most common (>20%) TEAEs grade≥ 3 were febrile neutropenia (46%) and lung infection (42%), while treatment-related AEs (any agent) grade≥ 3 were thrombocytopenia (12%), neutropenia (8%), QT prolongation (8%) and differentiation syndrome (DS) in 1 pt (4%) (grade 3). One other pt had grade 2 DS, and all DS resolved with steroids. There was no early mortality (60 days).

The overall response rate (CR+CRh+CRp+CRi+PR+MLFS) was 88% (23/26 pts). Among the 3 non-responders, 1 had prior menin inhibitor, and all had prior hypomethylating agent and venetoclax; two had large burden EMD with marked improvement and reduction of BM blasts <5% but residual activity on PET scan. The CR/CRh rate was 58% (15 pts), with a CR rate of 46% (12 pts), CRh of 12% (3 pts), CRp of 12% (3 pts), PR of 4% (1 pt), and MLFS of 15% (4 pts). The MRD-negative rate by flow cytometry among pts with CR/CRh was 93% (13/14 pts) and 74% among responders (17/23 pts). Notably, the MRD-negative rate was lowest in NUP98r pts at 20% (1/5 pts). Twelve pts received HSCT following this combination (46%), with 3 pts resuming maintenance revumenib post-HSCT.

With a median follow-up of 6.6 months, the 6-months relapse-free survival was 59% (95% CI: 26%-81%) and overall survival was 74% (95% CI: 39%-83%). The median duration of response in those with CR/CRh was not reached. Two pts have completed maintenance post-HSCT and remain in remission.

Conclusions: The all-oral combination SAVE results in high rates of remission in pts with R/R AML with KMT2Ar, NPM1mt or NUP98r. In addition to the R/R cohort, a frontline cohort is now enrolling pts.

Disclosures: Issa: Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: consultancy/ad board fees, Research Funding; Merck: Research Funding; Celgene: Research Funding; NuProbe: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: consultancy/ad board fees, Research Funding; Astex: Research Funding; Syndax Pharmaceuticals, Inc.: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: consultancy/ad board fees, Research Funding; AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: consultancy/ad board fees; Kura Oncology: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: consultancy/ad board fees, Research Funding; Sanofi: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: consultancy/ad board fees; AstraZeneca: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: consultancy/ad board fees. Cuglievan: Syndax Pharmaceuticals, Inc.: Other: travel, accommodations, Research Funding; LLS: Research Funding; Octapharma: Other: travel, accommodations, research; Kura Oncology: Research Funding. Daver: Gilead: Consultancy, Research Funding; Glycomimetics: Research Funding; Syndax: Consultancy; Agios: Consultancy; Trovagene: Research Funding; Arog: Consultancy; KITE: Research Funding; Servier: Consultancy, Research Funding; Bristol Myers Squibb: Consultancy, Research Funding; Daiichi-Sankyo: Consultancy, Research Funding; Novartis: Consultancy; Astellas: Consultancy, Research Funding; Celgene: Consultancy; Shattuck Labs: Consultancy; FATE Therapeutics: Other: Consulting Fees, Research Funding; Hanmi: Research Funding; Jazz: Consultancy; Trillium: Consultancy, Research Funding; Pfizer: Consultancy, Research Funding; Genentech: Consultancy, Research Funding; Novimmune: Research Funding; Menarini Group: Consultancy. DiNardo: Schrodinger: Consultancy, Honoraria; BMS: Consultancy, Honoraria, Research Funding; Cleave: Research Funding; Gilead: Consultancy; Abbvie: Consultancy, Honoraria, Research Funding; Servier: Consultancy, Honoraria, Other: meetingsupport, Research Funding; AstraZeneca: Honoraria; Astex: Research Funding; Immunogen: Honoraria; ImmuneOnc: Research Funding; Foghorn: Research Funding; Riegel: Honoraria; Notable Labs: Honoraria; Genetech: Honoraria; GenMab: Consultancy, Honoraria, Other: data safety board; Jazz: Consultancy, Honoraria; GSK: Consultancy, Honoraria; Loxo: Research Funding; Rigel: Research Funding; Astellas: Consultancy, Honoraria; Amgen: Consultancy; Stemline: Consultancy. Short: Amgen: Honoraria; Adaptive Biotechnologies: Honoraria; NextCure: Research Funding; Sanofi: Honoraria; Autolus: Honoraria; GSK: Consultancy, Research Funding; Astellas Pharma, Inc.: Honoraria, Research Funding; Stemline Therapeutics: Research Funding; Pfizer Inc.: Honoraria; BeiGene: Honoraria; Xencor: Research Funding; Novartis: Honoraria; Takeda Oncology: Honoraria, Research Funding. Yilmaz: daiichi sankyo: Honoraria, Research Funding. Kadia: Rigel: Honoraria; Regeneron: Research Funding; AstraZeneca: Research Funding; JAZZ: Research Funding; Abbvie: Consultancy, Research Funding; Amgen: Research Funding; Genentech: Consultancy, Research Funding; Ascentage: Research Funding; ASTEX: Research Funding; Sellas: Consultancy, Research Funding; Incyte: Research Funding; Pfizer: Research Funding; Servier: Consultancy; Cellenkos: Research Funding; Novartis: Honoraria; BMS: Consultancy, Research Funding; DrenBio: Consultancy, Research Funding. Pemmaraju: Incyte: Honoraria; Roche Molecular Diagnostics: Honoraria; Stemline Therapeutics: Honoraria, Other: Travel Expenses, Research Funding; Springer Science + Business Media: Honoraria; Mustang Bio: Honoraria, Other: Travel Expenses, Research Funding; Aptitude Health: Honoraria; Celgene: Honoraria, Other: Travel Expenses; LFB Biotechnologies: Honoraria; Protagonist Therapeutics: Consultancy; ClearView Healthcare Partners: Consultancy; Bristol-Myers Squibb: Consultancy; Neopharm: Honoraria; Immunogen: Consultancy; CTI BioPharma: Consultancy; Astellas: Consultancy; Novartis: Honoraria, Research Funding; DAVA Oncology: Honoraria, Other: Travel Expenses; Pacylex: Consultancy; CareDx: Honoraria; Blueprint Medicines: Consultancy, Honoraria; Daiichi Sankyo: Research Funding; Cellectis: Research Funding; Affymetrix/Thermo Fisher Scientific: Research Funding; Triptych Health Partners: Consultancy; Plexxikon: Research Funding; Samus Therapeutics: Research Funding; AbbVie: Honoraria, Other: Travel Expenses, Research Funding; Blueprint Medicines OncLive PeerView Institute for Medical Education: Consultancy, Other: advisory board; ASH Committee on Communications ASCO Cancer.NET Editorial Board: Other: Leadership; Karger Publishers: Other: Licenses; National Institute of Health/National Cancer Institute (NIH/NCI): Research Funding; HemOnc Times/Oncology Times: Other: uncompensated. Ohanian: Bio-Path Holdings, Inc.: Consultancy. Abbas: Genentech: Research Funding; Illumina: Honoraria, Other: Inkind Support, Research Funding; GlaxoSmithKline: Research Funding; Alamar Biosciences: Honoraria; Molecular Partners: Consultancy; Blueprint Medicines Corporation: Research Funding; Ascentage: Research Funding; Enzyme By Design: Research Funding. Maiti: Chimeric Therapeutics: Research Funding; Lin Biosciences: Research Funding; Hibercell Inc.: Research Funding; CytoMed Therapeutics: Research Funding; Indapta Therapeutics: Research Funding; Inspirna: Research Funding. Jabbour: AbbVie, Adaptive Biotechnologies, Amgen, Astellas Pharma, BMS, Genentech, Incyte, Pfizer, Takeda: Consultancy; AbbVie, Adaptive Biotechnologies, Amgen, Ascentage Pharma Group, Pfizer, Takeda: Research Funding. Sasaki: Otsuka: Other: Lecture fees; Enliven: Research Funding; Novartis: Consultancy, Research Funding; Pfizer: Consultancy; Daiichi-Sankyo: Consultancy; Chugai: Other: Lecture fees. Borthakur: Catamaran Bio, AbbVie, PPD Development, Protagonist Therapeutics, Janssen: Consultancy; Pacylex, Novartis, Cytomx, Bio Ascend: Membership on an entity's Board of Directors or advisory committees; Astex Pharmaceuticals, Ryvu, PTC Therapeutics: Research Funding. Montalban-Bravo: Takeda: Research Funding; Rigel: Research Funding. Jain: Incyte: Research Funding; Precision Biosciences: Consultancy, Honoraria, Other: Travel Support, Research Funding; Medisix: Research Funding; Ipsen: Consultancy, Honoraria, Other: Travel Support; Loxo Oncology: Research Funding; Takeda: Research Funding; Janssen: Consultancy, Honoraria, Other: Travel Support; NovalGen: Research Funding; Dialectic Therapeutics: Research Funding; Kite, a Gilead Company: Consultancy, Honoraria, Other: Travel Support, Research Funding; MingSight: Honoraria, Research Funding; Servier: Research Funding; Bristol Myers Squibb: Consultancy, Honoraria, Other: Travel Support, Research Funding; TransThera Sciences: Research Funding; MEI Pharma: Consultancy, Honoraria, Other: Travel Support; Genentech: Consultancy, Honoraria, Other: Travel Support, Research Funding; Pfizer: Research Funding; Newave: Research Funding; ADC Therapeutics: Research Funding; Fate Therapeutics: Research Funding; Pharmacyclics: Consultancy, Honoraria, Other: Travel Support, Research Funding; Aprea Therapeutics: Research Funding; Cellectis: Consultancy, Honoraria, Other: Travel Support, Research Funding; TG Therapeutics: Consultancy, Honoraria, Other: Travel Support; CareDx: Consultancy, Honoraria, Other: Travel Support; BeiGene: Consultancy, Honoraria, Other: Travel Support; AstraZeneca: Consultancy, Honoraria, Other: Travel Support, Research Funding; Adaptive Biotechnologies: Consultancy, Honoraria, Other: Travel Support, Research Funding; AbbVie: Consultancy, Honoraria, Other: Travel Support, Research Funding. Ravandi: Prelude: Consultancy, Honoraria, Research Funding; Syros: Consultancy, Honoraria, Research Funding; Amgen: Research Funding; Xencor: Research Funding; Abbvie: Consultancy, Honoraria; BMS: Consultancy, Honoraria; Astellas: Consultancy, Honoraria; Astyex/Taiho: Research Funding; Syndax: Honoraria. Garcia-Manero: Janssen: Research Funding; Merck: Research Funding; Genentech: Other: Personal fees; AbbVie: Research Funding; Curis: Research Funding; Bristol Myers Squibb: Other: Personal fees, Research Funding; Genentech: Research Funding; Astex: Research Funding; Helsinn: Other: Personal fees; Helsinn: Research Funding; Astex: Other: Personal fees; Onconova: Research Funding; Aprea: Research Funding; H3 Biomedicine: Research Funding; Forty Seven: Research Funding; Novartis: Research Funding; Amphivena: Research Funding. Andreeff: Daiichi-Sankyo: Research Funding; Syndax: Honoraria, Research Funding; Aptose: Honoraria; Kintor Pharmaceutical: Research Funding; Paraza: Honoraria; Glycomimetics: Honoraria; Ona: Honoraria; Sellas: Honoraria, Research Funding; Oxford Biomedical: Research Funding; Roivant: Honoraria; Eterna: Current holder of stock options in a privately-held company, Honoraria, Research Funding; Ellipses: Research Funding; SentiBio: Current holder of stock options in a privately-held company, Honoraria, Research Funding; Oncolyze: Current holder of stock options in a privately-held company; Boehringer-Ingelheim: Honoraria; Chimerix: Current holder of stock options in a privately-held company. Kantarjian: AbbVie, Amgen, Ascentage, Ipsen Biopharmaceuticals, KAHR Medical, Novartis, Pfizer, Shenzhen Target Rx, Stemline,Takeda: Consultancy, Honoraria.

<< Previous Abstract | Next Abstract
*signifies non-member of ASH